Investigational benign prostatic hyperplasia drug improves urgency, frequency
Patients receiving NX-1207, an investigational drug for BPH, experienced significant quantitative improvement in urgency and frequency of urination, according to Nymox Pharmaceuticals, the drug's manufacturer.
Patients receiving NX-1207, an investigational drug for BPH, experienced significant quantitative improvement in urgency and frequency of urination, according to Nymox Pharmaceuticals, the drug’s manufacturer.
Compared with baseline, symptoms of urgency were reduced by 47% at 90 days after a single treatment with NX-1207 (pp
Compared with baseline, frequency of urination was reduced by 43% at 90 days (pp
The drug is administered in an office setting directly into the zone of the prostate where the enlargement occurs. NX-1207 has not been found to have sexual side effects or effects on blood pressure.
